Skip to main content

Table 3 Unadjusted associations between surfactant protein A (SFTPA1,SFTPA2) haplotypes and persistent cough or wheeze in the first year of life.a Unadjusted odds ratios (OR) and 95% confidence intervals (CI) are from ordered logistic regression models predicting symptom frequency. b (CT and MA, 1998 – 2000)

From: Respiratory symptoms among infants at risk for asthma: association with surfactant protein A haplotypes

Allele, haplotypec

Nucleotide/amino acidd

Estimated Frequency Distributione% (95% CI)

Persistent Cough OR (95% CI)

Wheeze OR (95% CI)

SFTPA1

aa 19

aa 50

aa 62

aa 133

aa 219

   

   6A

C/Ala

C/Leu

G

G

C/Arg

6.1% (4.0 – 8.3)

3.69 (1.71, 7.98)

4.72 (2.20, 10.11)

   6A 2

T/Val

G/Val

A

A

C/Arg

54.0% (49.3 – 58.7)

1.18 (0.63, 2.19)

1.13 (0.60, 2.14)

   6A 3

T/Val

C/Leu

A

A

C/Arg

25.6% (21.6 – 29.6)

0.81 (0.49, 1.36)

0.83 (0.49, 1.40)

   6A 4

T/Val

C/Leu

G

A

T/Trp

6.2% (4.1 – 8.4)

0.94 (0.44, 2.03)

0.70 (0.31, 1.60)

   all others

     

8%

  

SFTPA2

aa 9

aa 91

aa 140

aa 223

    

   1A

C/Thr

C/Pro

C

C/Gln

 

8.4% (6.0 – 10.8)

1.53 (0.75, 3.14)

1.30 (0.63, 2.71)

   1A 0

A/Asn

G/Ala

C

C/Gln

 

54.2% (49.5 – 58.8)

1.13 (0.60, 2.13)

1.14 (0.59, 2.19)

   1A 1

C/Thr

G/Ala

T

A/Lys

 

13.7% (10.7 – 16.7)

0.82 (0.45, 1.48)

0.87 (0.47, 1.58)

   1A 2

C/Thr

G/Ala

C

C/Gln

 

10.2% (7.6 – 12.7)

0.95 (0.49, 1.84)

0.83 (0.42, 1.64)

   1A 3

A/Asn

G/Ala

T

A/Lys

 

1.8% (0.7 – 2.9)

0.45 (0.08, 2.48)

0.55 (0.10, 3.06)

   1A 5

C/Thr

C/Pro

T

C/Gln

 

4.6% (2.7 – 6.5)

0.43 (0.15, 1.23)

0.66 (0.24, 1.79)

   1A 6

C/Thr

G/Ala

T

C/Gln

 

3.2% (1.7 – 4.7)

1.41 (0.49, 4.05)

1.54 (0.54, 4.39)

   all others

     

4%

  

SFTPA Haplotype

        

   6A/1A

     

5.4% (3.2 – 7.2)

3.20 (1.39, 7.36)

3.25 (1.43, 7.37)

   6A 2 /1A 0

     

49.0% (44.4 – 53.6)

1.20 (0.66, 2.19)

1.04 (0.57, 1.90)

   6A 2 /1A 2

     

1.8% (0.6 – 2.9)

1.43 (0.36, 5.70)

0.26 (0.03, 1.99)

   6A 2 /1A 3

     

1.0% (0.2 – 1.9)

0.65 (0.10, 4.39)

0.79 (0.11, 5.47)

   6A 3 /1A 0

     

4.7% (2.8 – 6.6)

1.16 (0.49, 2.74)

0.92 (0.37, 2.31)

   6A 3 /1A 1

     

11.3% (8.5 – 14.1)

1.12 (0.60, 2.08)

1.08 (0.57, 2.04)

   6A 3 /1A 2

     

5.6% (3.6 – 7.6)

0.93 (0.40, 2.16)

0.92 (0.39, 2.17)

   6A 3 /1A 6

     

1.7% (0.5 – 2.8)

0.91 (0.21, 4.07)

2.26 (0.55, 9.33)

   6A 4 /1A 5

     

2.9% (1.4 – 4.4)

0.28 (0.07, 1.07)

0.30 (0.08, 1.20)

   6A 4 /1A 6

     

1.8% (0.6 – 3.0)

1.88 (0.49, 7.16)

1.69 (0.44, 6.39)

   Others

     

14.9%

  
  1. aAnalyses included infants with complete data for both SFTPA alleles and respiratory symptoms, i.e., for SFTPA1 and persistent cough (N = 203) or wheeze (N = 202); SFTPA2 and persistent cough (N = 205) or wheeze (N = 204); SFTPA and persistent cough (N = 201) or wheeze (N = 200). bSeparate ordered logistic regression analyses were performed for each outcome measure and each haplotype with all other haplotypes serving as the reference group in each model. All model results (ORs [95% CI]) include estimates of model variabillity due to ambiguity in allele haplotype assignment (see text). Number of days per year of symptoms were included in models as a 6-category variable, i.e., 0, 1–7, 8–14, 15–21, 22–28, > 28 days. Significant results (p < 0.05) are in bold-face type. c By convention, SFTPA1 allele haplotypes are denoted by 6An and SFTPA2 allele haplotypes by 1Am [17,21]. daa 62, aa 133 and aa 140 are silent. eEstimated frequency distribution of haplotypes (mean, 95% CI) for white infants.
Back to article page

BMC Medical Genetics

ISSN: 1471-2350

Contact us